Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

Why does NZ suck at building brands
Markets

Eden Bradfield: Why does NZ suck at building brands

Let the French have Fonterra brands, Eden Bradfield writes.

Eden Bradfield 06 Sep 2025
NZ sharemarket ends week up 2.2%
Markets Market Close

NZ sharemarket ends week up 2.2%

The S&P/NZX 50 Index closed at 13,223.53, up 90.32 points or 0.69%.

Graham Skellern 05 Sep 2025
Fletcher Building slashes maximum CEO pay
Markets

Fletcher Building slashes maximum CEO pay

 Total maximum remuneration is now $2m lower at $5.8m.

Rebecca Howard 05 Sep 2025
Westpac NZ eyes monetary policy reform for change-laden RBNZ
Economy

Westpac NZ eyes monetary policy reform for change-laden RBNZ

Westpac NZ puts monetary policy voting in the spotlight.

Staff reporters 05 Sep 2025